Table 4.
Stratified Cox proportional hazard model for the risk of all-cause mortality, locoregional recurrence, and distant metastasis among patients with cervical adenocarcinoma or squamous cell carcinoma who received definitive concurrent chemoradiotherapy
| FIGO stage | Event | Pathologic type | Event no (%) | Adjusted HR* (95% CI) | P value |
|---|---|---|---|---|---|
| All patients | All-cause mortality | SCC | 1081 (36.93) | ref. | < .0001 |
| adenocarcinoma | 183 (55.29) | 2.10 (1.79-2.46) | |||
| Locoregional recurrence | SCC | 364 (12.44) | ref. | < .0001 | |
| adenocarcinoma | 58 (17.52) | 1.79 (1.35-2.37) | |||
| Distant metastasis | SCC | 428 (14.62) | ref. | < .0001 | |
| adenocarcinoma | 75 (22.66) | 1.97 (1.54-2.53) | |||
| Stage I | All-cause mortality | SCC | 100 (22.83) | ref. | .0004 |
| adenocarcinoma | 27 (39.71) | 2.21 (1.43-3.42) | |||
| Locoregional recurrence | SCC | 44 (10.05) | ref. | .0047 | |
| adenocarcinoma | 14 (20.59) | 2.58 (1.37-4.86) | |||
| Distant metastasis | SCC | 53 (12.10) | ref. | .2351 | |
| adenocarcinoma | 11 (16.18) | 1.50 (0.77-2.93) | |||
| Stage II | All-cause mortality | SCC | 420 (29.45) | ref. | < .0001 |
| adenocarcinoma | 71 (47.65) | 2.26 (1.75-2.92) | |||
| Locoregional recurrence | SCC | 178 (12.48) | ref. | .0026 | |
| adenocarcinoma | 29 (19.46) | 1.84 (1.24-2.74) | |||
| Distant metastasis | SCC | 175 (12.27) | ref. | < .0001 | |
| adenocarcinoma | 36 (24.16) | 2.31 (1.61-3.32) | |||
| Stage III-IV | All-cause mortality | SCC | 561 (52.78) | ref. | < .0001 |
| adenocarcinoma | 85 (74.56) | 2.05 (1.62-2.59) | |||
| Locoregional recurrence | SCC | 142 (13.36) | ref. | .1672 | |
| adenocarcinoma | 15 (13.16) | 1.47 (0.85-2.52) | |||
| Distant metastasis | SCC | 200 (18.81) | ref. | .0020 | |
| adenocarcinoma | 28 (24.56) | 1.90 (1.27-2.86) |
*
All variables presented in Table 2 were used in the multivariate analysis.
SCC, squamous cell carcinoma; ADC, adenocarcinoma; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio.